3/13
02:48 pm
mcrb
Seres Therapeutics (MCRB) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $22.00 price target on the stock.
Low
Report
Seres Therapeutics (MCRB) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $22.00 price target on the stock.
3/12
07:00 am
mcrb
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Low
Report
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
3/3
10:05 am
mcrb
Microbiome Market Competitive Landscape Report 2026: Comprehensive Insights About 140+ Companies and 180+ Drugs [Yahoo! Finance]
Low
Report
Microbiome Market Competitive Landscape Report 2026: Comprehensive Insights About 140+ Companies and 180+ Drugs [Yahoo! Finance]
3/2
04:34 pm
mcrb
Seres Therapeutics appoints Richard Kender as interim CEO [Seeking Alpha]
Low
Report
Seres Therapeutics appoints Richard Kender as interim CEO [Seeking Alpha]
3/2
04:22 pm
mcrb
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates [Yahoo! Finance]
Low
Report
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates [Yahoo! Finance]
3/2
04:05 pm
mcrb
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
Low
Report
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
2/12
07:00 am
mcrb
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
High
Report
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
2/6
06:36 pm
mcrb
Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold' [Seeking Alpha]
Low
Report
Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold' [Seeking Alpha]
1/6
07:00 am
mcrb
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
Low
Report
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy